Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl

Scleromyositis is a rare autoimmune disease characterized by overlapping scleroderma and myositis. This case report discusses the presentation and management of a 28-year-old male with scleromyositis presenting with myositis, arthritis, Raynaud’s phenomenon, refractory calcinosis, interstitial lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Álvarez Troncoso, Jorge, Nuño González, Almudena, Martínez Robles, Elena, Sorriguieta Torre, Raquel, Robles Marhuenda, Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947514/
https://www.ncbi.nlm.nih.gov/pubmed/36843820
http://dx.doi.org/10.7759/cureus.34125
_version_ 1784892572270854144
author Álvarez Troncoso, Jorge
Nuño González, Almudena
Martínez Robles, Elena
Sorriguieta Torre, Raquel
Robles Marhuenda, Ángel
author_facet Álvarez Troncoso, Jorge
Nuño González, Almudena
Martínez Robles, Elena
Sorriguieta Torre, Raquel
Robles Marhuenda, Ángel
author_sort Álvarez Troncoso, Jorge
collection PubMed
description Scleromyositis is a rare autoimmune disease characterized by overlapping scleroderma and myositis. This case report discusses the presentation and management of a 28-year-old male with scleromyositis presenting with myositis, arthritis, Raynaud’s phenomenon, refractory calcinosis, interstitial lung disease, and myocarditis. This case highlights key points in the systematic approach to immunosuppressive treatment and proposes a novel therapeutic option.
format Online
Article
Text
id pubmed-9947514
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-99475142023-02-24 Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl Álvarez Troncoso, Jorge Nuño González, Almudena Martínez Robles, Elena Sorriguieta Torre, Raquel Robles Marhuenda, Ángel Cureus Internal Medicine Scleromyositis is a rare autoimmune disease characterized by overlapping scleroderma and myositis. This case report discusses the presentation and management of a 28-year-old male with scleromyositis presenting with myositis, arthritis, Raynaud’s phenomenon, refractory calcinosis, interstitial lung disease, and myocarditis. This case highlights key points in the systematic approach to immunosuppressive treatment and proposes a novel therapeutic option. Cureus 2023-01-24 /pmc/articles/PMC9947514/ /pubmed/36843820 http://dx.doi.org/10.7759/cureus.34125 Text en Copyright © 2023, Álvarez Troncoso et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Álvarez Troncoso, Jorge
Nuño González, Almudena
Martínez Robles, Elena
Sorriguieta Torre, Raquel
Robles Marhuenda, Ángel
Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
title Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
title_full Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
title_fullStr Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
title_full_unstemmed Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
title_short Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
title_sort tofacitinib is an effective treatment for refractory scleromyositis associated with anti-pm/scl
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947514/
https://www.ncbi.nlm.nih.gov/pubmed/36843820
http://dx.doi.org/10.7759/cureus.34125
work_keys_str_mv AT alvareztroncosojorge tofacitinibisaneffectivetreatmentforrefractoryscleromyositisassociatedwithantipmscl
AT nunogonzalezalmudena tofacitinibisaneffectivetreatmentforrefractoryscleromyositisassociatedwithantipmscl
AT martinezrobleselena tofacitinibisaneffectivetreatmentforrefractoryscleromyositisassociatedwithantipmscl
AT sorriguietatorreraquel tofacitinibisaneffectivetreatmentforrefractoryscleromyositisassociatedwithantipmscl
AT roblesmarhuendaangel tofacitinibisaneffectivetreatmentforrefractoryscleromyositisassociatedwithantipmscl

Ejemplares similares